Abstract
Given the rapid progression of the coronavirus disease 2019(COVID-19)pandemic,an ultrafast response was urgently required to handle this major public crisis.To contain the pandemic,investments are required to develop diagnostic tests,prophylactic vaccines,and novel therapies.Lately,nucleoside analog(NA)antivirals topped the scene as top options for the treatment of COVID-19 caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infections.Meanwhile,the continuous generation of new lineages of the SARS-CoV-2 Omicron variant caused a new challenge in the persistent COVID-19 battle.Hitting the two crucial SARS-CoV-2 enzymes RNA-dependent RNA polymerase(RdRp)and 3’-to-5'exoribonuclease(ExoN)collectively together using only one single ligand is a very successful new approach to stop SARS-CoV-2 multiplication and combat COVID-19 irrespective of the SARS-CoV-2 variant type because RdRps and ExoNs are broadly conserved among all SARS-CoV-2 strains.Herein,the current comprehensive study investigated most NAs libraries,searching for the most ideal drug candidates expectedly able to perfectly act through this double tactic.Gradual computational filtration gave rise to six different promising NAs,which are riboprine,forodesine,tecadenoson,nelarabine,vidarabine,and maribavir,respectively.Further biological assessment proved for the first time,using the in vitro anti-RdRp/ExoN and anti-SARS-CoV-2 bioassays,that riboprine and forodesine,among all the six tested NAs,are able to powerfully inhibit the replication of the new virulent strains of SARS-CoV-2 with extremely minute in vitro anti-RdRp and anti-SARS-CoV-2 EC50 values of about 0.22 and 0.49 μM for riboprine and about 0.25 and 0.73 μM for forodesine,respectively,surpassing both remdesivir and the new anti-COVID-19 drug molnupiravir.The prior in silico data supported these biochemical findings,suggesting that riboprine and forodesine molecules strongly hit the key catalytic pockets of the SARS-CoV-2(Omicron variant)RdRp’s and ExoN’s main active sites.Additionally,the ideal pharmacophoric features of riboprine and forodesine molecules render them typical dual-action inhibitors of SARS-CoV-2 replication and proofreading,with their relatively flexible structures open for diverse types of chemical derivatization.In Brief,the current important results of this comprehensive study revealed the interesting repurposing potentials of,mainly,the two nucleosides riboprine and forodesine to effectively shut down the polymerase/exoribonuclease-RNA nucleotides interactions of the SARS-CoV-2 Omicron variant and consequently treat COVID-19 infections,motivating us to rapidly begin the two drugs'broad preclinical/clinical anti-COVID-19 bioevaluations,hoping to combine both drugs soon in the COVID-19 treatment protocols.
NSTL